Osteoporosis Market to Accelerate Substantially, Assesses DelveInsight | Key Companies to Look Out For - Teva, Novartis, Amgen, USB, Jiangsu HengRui Medicine, Shanghai JMT-Bio, Eli Lilly and Company, Celltrion

The current therapeutic landscape of osteoporosis in the 7MM is driven by current treatment practices and the expected launch of emerging therapies. The current osteoporosis market witnesses the use of several approved therapies available in different therapeutic classes.

LAS VEGAS, June 22, 2023 /PRNewswire/ -- DelveInsight's Osteoporosis Market Insights report includes a comprehensive understanding of current treatment practices, osteoporosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Osteoporosis Market Report

• As per DelveInsight analysis, the osteoporosis market is expected to grow positively at a significant CAGR during the study period (2019–2032).
• According to the DelveInsight estimates, the total diagnosed prevalent population of osteoporosis in the seven major markets was ~30 million cases in 2021. While, the total diagnosed prevalent population of osteoporosis in the United States was found to be ~7 million cases in 2021, which is expected to increase by 2032.
• Globally, leading osteoporosis companies such as Teva Pharmaceuticals, Novartis, Amgen, USB, Gedeon Richter Plc., Luye Pharma, Haoma Medica, Jiangsu HengRui Medicine, Shanghai JMT-Bio Inc., Transcenta Holding, Celltrion, Enzene Biosciences, Fresenius Kabi, Gedeon Richter, Samsung Bioepis, Alvotech, MAbxience, Shanghai Henlius Biotech, Rani therapeutics, Entera Bio, Paras Biopharmaceuticals, Shenzhen Salubris Pharmaceutical, Enteris Biopharma, Prestige Biopharma, Shinpoong Ltd., Shanghai Biomabs Pharmaceutical, Angitia Biopharmaceuticals, Dongkook pharmaceutical, Biocon Biologics UK Ltd, Bonus BioGroup Ltd., Cellatoz Therapeutics, Inc., Keros Therapeutics, Clayton Biotechnologies, Novadip, Eli Lilly and Company, Hexal, Sandoz, Solarea Bio, and others are developing novel osteoporosis drugs that can be available in the osteoporosis market in the coming years.
• Some key therapies for osteoporosis treatment include TVB-009, Zoledronic Acid, Romosozumab, RGB-14-P, Denosumab biosimilar, NaQuinate, SHR-1222, and others.

Discover which therapies are expected to grab the major osteoporosis market share @ Osteoporosis Market Report

Osteoporosis Overview

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural degeneration of bone tissue, resulting in increased bone fragility and fracture risk. Hyperparathyroidism, hyperglycemia, medicines, smoking, alcohol usage, oxidative stress, inflammation, calcium deficiency, menopause, and other factors can all contribute to osteoporosis. The most common osteoporosis symptoms are a vertebral compression fracture or a hip fracture. Compression fractures in the spine caused by weaker vertebrae can cause mid-back pain. The fractures normally heal on their own, and the discomfort subsides; nevertheless, the pain can sometimes persist because the crushed bone continues to move and shatter. Symptoms include loss of height, back pain, an increase in the number of bed days, depression, and others. The National Osteoporosis Foundation, the American Medical Association, and other major medical organizations recommend a dual-energy X-ray absorptiometry scan (DXA, formerly known as DEXA) to reliably detect the occurrence of osteoporosis.

Osteoporosis Epidemiology Segmentation

The osteoporosis epidemiology section provides insights into the historical and current osteoporosis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The osteoporosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Osteoporosis Prevalence 
• Osteoporosis Diagnosed Prevalence
• Osteoporosis Gender-specific Prevalence
• Primary Osteoporosis Prevalence
• Secondary Osteoporosis Prevalence
• Osteoporosis-related Comorbidities
• Incidence of Osteoporotic Fractures

Osteoporosis Treatment Market 

Osteoporosis treatment entails treating and preventing fractures, as well as using medications to rebuild weak bones. According to the International Osteoporosis Foundation, pharmacological therapies are required for those at high risk to successfully minimize the risk of fractured bones due to osteoporosis. Treatments have been demonstrated to reduce the risk of hip fracture by up to 40%, vertebral fractures by 30-70%, and non-vertebral fractures by 15-20% with various drugs.

The osteoporosis treatment landscape is dominated by pharmacological therapies, which are further classified as anti-resorptive agents (such as bisphosphonates, estrogen agonist/antagonists (EAAs), estrogens, calcitonin, and denosumab), anabolic agents (such as teriparatide and abaloparatide), and mixed agents (such as Romosozumab). Apart from the aforementioned pharmacotherapies, further anti-resorptive treatment options for osteoporosis include estrogen replacement and selective estrogen receptor modulators, which include raloxifene, lasofoxifene, and bazedoxifene. Furthermore, a few dietary supplements, such as calcium and vitamin D, can help patients with osteoporosis.

Major therapeutic improvements in osteoporosis treatment have been made in recent years as scientists obtain a better knowledge of the bone shape and the underlying mechanisms that cause osteoporosis. In the current context, the market for osteoporosis is dominated by current therapy approaches, with fewer treatments in various phases of development. The anticipated introduction of a few therapies may enhance market size in the following years for the forecast period 2023–2032. 

To know more about osteoporosis treatment, visit @ Osteoporosis Treatment Drugs 

Key Osteoporosis Therapies and Companies

• TVB-009: Teva Pharmaceuticals
• Zoledronic Acid: Novartis
• Romosozumab: Amgen/USB
• RGB-14-P: Gedeon Richter Plc.
• Denosumab biosimilar: Luye Pharma
• NaQuinate: Haoma Medica
• SHR-1222: Jiangsu HengRui Medicine

Learn more about the FDA-approved drugs for osteoporosis @ Drugs for Osteoporosis Treatment 

Osteoporosis Market Dynamics

The dynamics of the osteoporosis market are expected to change in the coming years. The availability of several current treatment options is the primary strength of the osteoporosis market. In addition, thriving research and development to comprehend the disease's diversity may improve osteoporosis diagnosis, culminating in a profitable commercial potential. Moreover, several organizations are actively striving to raise awareness and give information on osteoporosis. As a result, there is a rising demand for available therapeutic approaches, which is propelling the osteoporosis market.

Furthermore, the expected introduction of emerging therapies and a further improvement in the diagnosis rate are likely to boost the growth of the osteoporosis market in the 7MM. Moreover, the pipeline for osteoporosis is quite robust; many prospective therapies are being researched for osteoporosis treatment, and it is safe to expect that the osteoporosis treatment space will have a substantial impact on the osteoporosis market throughout the forecast period. 

However, several factors are impeding the growth of the osteoporosis market. The majority of patients suffer from brittle bone, which necessitates lengthy therapy interventions. Anti-resorptive medicines only slightly raise bone mineral density and lower the incidence of non-vertebral fractures by 20%, which is quite low. Moreover, the existing therapy alternatives have a number of side effects, resulting in a treatment gap. The diagnosis of osteoporosis is regarded to be substantially underdiagnosed, resulting in therapy for the condition. 

Furthermore, the osteoporosis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the osteoporosis market growth. 

Scope of the Osteoporosis Market Report

• Therapeutic Assessment: Osteoporosis current marketed and emerging therapies
• Osteoporosis Market Dynamics: Attribute Analysis of Emerging Osteoporosis Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's Views, Analyst's Views, Osteoporosis Market Access and Reimbursement

Discover more about osteoporosis drugs in development @ Osteoporosis Clinical Trials

Table of Contents

Related Reports

Osteoporosis Pipeline

Osteoporosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Osteoporosis companies, including Shanghai JMT-Bio Inc., Transcenta Holding, Celltrion, Sandoz, Enzene Biosciences, Fresenius Kabi, Gedeon Richter, Samsung Bioepis, Alvotech, MAbxience, Shanghai Henlius Biotech, among others.

Osteoporosis Epidemiology Forecast

Osteoporosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted osteoporosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Post-Menopausal  Osteoporosis Pipeline

Post-Menopausal  Osteoporosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key post-menopausal osteoporosis companies, including Teva Pharmaceutical, Eli Lilly and Company, HEXAL, Celltrion, among others.

Post-Menopausal  Osteoporosis Market

Post-Menopausal  Osteoporosis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key post-menopausal osteoporosis companies including Teva Pharmaceutical, Eli Lilly and Company, HEXAL, Celltrion, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur  
info@delveinsight.com  
+1(919)321-6187 
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg